Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

About this update from Revelation Biosciences, Inc.

[{"type":"text","content":"SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.","length":330,"tagName":"p"},{"type":"text","content":"Corporate Highlights","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Received net proceeds of $6.7 million from warrant inducement in January 2026","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic priorities","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026)","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiated discussions with potential clinical research organizations for the single adaptive Phase 2/3 study","length":108,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":665,"olType":false},{"type":"text","content":""The incredible momentum achieved in 2025 is continuing in 2026," said James Rolke, Chief Executive Officer of Revelation. "Our focus remains on getting our pivotal clinical study of Gemini in acute kidney patients underway for the benefit of those patients and ultimately to deliver significant value for our shareholders."","length":344,"tagName":"p"},{"type":"text","content":"Results of Operations","length":21,"tagName":"p"},{"type":"text","content":"As of March 31, 2026, Revelation had $14.1 million in cash and cash equivalents, compared to $10.7 million as of December 31, 2025. The increase in cash and cash equivalents was primarily due to net cash proceeds from the January 2026 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections,...

More updates from Revelation Biosciences, Inc.